Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 11, 2026
STERIS plc (STE): Q4 Earnings Preview and What Investors Should Watch

STERIS plc (STE): Q4 Earnings Preview and What Investors Should Watch

Key Takeaways

  • Analysts expect Q4 fiscal 2026 revenue of approximately $1.60 billion, up about 8% year-over-year.
  • Consensus adjusted EPS estimate stands at $2.89, reflecting 5.5% growth from $2.74 in the prior-year quarter.
  • STERIS reaffirmed fiscal 2026 guidance for 8-9% revenue growth and adjusted EPS of $10.15-$10.30, factoring in tariff impacts.
  • Q3 results showed 9% revenue growth to $1.50 billion and adjusted EPS of $2.53, meeting expectations amid tariff headwinds.
  • Investors will focus on segment performance in Healthcare, Applied Sterilization Technologies (AST), and Life Sciences.
  • Historical post-earnings moves have been mixed, with positive reactions about 53% of the time over five years.

Earnings Context and Why It Matters

As STERIS plc (STE) wraps up its fiscal 2026 with this Q4 report—covering the quarter ended March 31, 2026—I'm keeping a close eye on how the company navigates ongoing demand for infection prevention and sterilization solutions in healthcare. STERIS reports on a fiscal calendar ending June 30 for Q1, September 30 for Q2, December 31 for Q3, and March 31 for Q4. From what I see, revenue growth has been fueled by volume increases, pricing actions, and strategic acquisitions, making this release pivotal for confirming guidance against an estimated $55 million pre-tax tariff hit. In my view, investors like us need to assess margin resilience here, especially with supply chain pressures and the gradual recovery in procedural volumes shaping valuations across the medical devices sector.

Earnings Expectations

Looking at the numbers, analysts are forecasting Q4 revenue of around $1.60 billion, marking roughly 8% growth from $1.48 billion a year ago. This fits squarely with the company's guidance for full-year 8-9% as-reported growth and 7-8% constant currency organic growth. The consensus adjusted EPS comes in at $2.89, a 5.5% rise from $2.74 in Q4 FY2025, which supports the full-year outlook of $10.15-$10.30 even with tariff pressures. One thing that stands out are the key metrics: procedure volumes in the Healthcare segment, utilization rates at Applied Sterilization Technologies (AST) for end-of-line medical device processing, and demand for consumables in Life Sciences.

For context, Q3 FY2026 (ended December 31, 2025) delivered $1.50 billion in revenue, up 9% year-over-year with 8% constant currency organic growth, and adjusted EPS of $2.53 that met expectations. Historically, STE has seen mixed post-earnings reactions—positive about 53% of the time over the past five years, with median gains of 6% on those up days. I also checked this using Tickeron’s AI Screener to gauge how the stock stacks up against peers on technical patterns and fundamentals leading into this report.

Market Reaction and Investor Sentiment

Sentiment heading into earnings feels cautiously optimistic to me. Shares of STE are down about 3% recently, trading around $207 amid broader market headwinds. Analysts hold a "Moderate Buy" rating, with price targets in the $275-$287 range that suggest roughly 30% upside potential. That said, risks like tariff costs exceeding $55 million or softer procedure volumes loom large; on the flip side, beats on guidance could trigger rallies, given those historical 6% median positive moves.

Forward Outlook and Key Factors to Monitor

Entering fiscal 2027, STERIS carries momentum from steady organic growth, but I'll be tracking how full-year results stack up against guidance. Confirming 8-9% revenue expansion and EPS around the $10.25 midpoint will be crucial, particularly as tariffs squeeze margins.

Key areas to watch include recovery in the Healthcare segment as elective procedures stabilize, AST capacity expansions to handle rising device sterilization needs, and ongoing strength in Life Sciences from biopharma consumables. Updates on tariff mitigation strategies, supply chain costs, and currency impacts—assumed neutral—will matter too.

Longer term, M&A activity and guided free cash flow of $850 million should continue supporting dividends and buybacks. The post-COVID emphasis on infection control strengthens STERIS's positioning, though hospital capital spending and competitive pressures deserve monitoring.

Why I Rely on Tickeron’s AI Screener

In my own research and trading process, I’ve found Tickeron’s AI Screener invaluable for cutting through the noise. This AI-powered tool lets me scan thousands of stocks and ETFs using customizable filters on technical patterns, fundamentals, trends, volatility, and AI signals—spotting trade ideas, breakouts, and opportunities far faster than manual methods. It’s become a staple for comparing names like STE to industry peers efficiently.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: STE

Momentum Indicator for STE turns negative, indicating new downward trend

STE saw its Momentum Indicator move below the 0 level on May 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In of the 93 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for STE turned negative on June 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

STE moved below its 50-day moving average on May 22, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STE's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where STE advanced for three days, in of 323 cases, the price rose further within the following month. The odds of a continued upward trend are .

STE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.794) is normal, around the industry mean (10.971). P/E Ratio (25.968) is within average values for comparable stocks, (63.498). Projected Growth (PEG Ratio) (1.397) is also within normal values, averaging (3.715). Dividend Yield (0.012) settles around the average of (0.018) among similar stocks. P/S Ratio (3.425) is also within normal values, averaging (23.956).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. STE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 5.43B. The market cap for tickers in the group ranges from 1.86K to 154.45B. ABT holds the highest valuation in this group at 154.45B. The lowest valued company is CSAY at 1.86K.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -3%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was -15%. TLSI experienced the highest price growth at 31%, while ICCM experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was 17% and the average quarterly volume growth was 180%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 76
Price Growth Rating: 61
SMR Rating: 90
Profit Risk Rating: 95
Seasonality Score: 25 (-100 ... +100)
View a ticker or compare two or three
STE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of surgical and other medical supplies

Industry MedicalNursingServices

Profile
Details
Industry
Medical Specialties
Address
5960 Heisley Road
Phone
+1 440 354-2600
Employees
17000
Web
https://www.steris-ir.com
Interact to see
Advertisement
Teradyne (TER), a leader in automated test equipment and industrial robotics, has demonstrated resilient performance amid a favorable semiconductor market cycle. In recent weeks, the stock has maintained upward traction, outperforming broader indices like the Nasdaq, supported by AI-driven demand for chip testing solutions.
Curtiss-Wright Corporation (CW) has demonstrated resilience in recent trading sessions, navigating a period of moderate volatility within the aerospace and defense sector. The stock has shown upward momentum over the latest market cycle, supported by strong demand in commercial and military applications.
CrowdStrike Holdings (CRWD) has shown resilience in the cybersecurity sector amid broader market cycles, with shares experiencing moderate pullbacks in recent weeks following strong year-to-date gains. The stock trades near its upper range, reflecting investor optimism in AI-driven security innovations and platform adoption.
Arista Networks (ANET) has demonstrated resilience in recent trading sessions amid fluctuating tech market conditions. The stock has navigated broader sector headwinds, including competition in cloud networking and varying demand from hyperscale clients.
Galaxy Digital Holdings Ltd. (GLXY), a leading player in digital assets and blockchain investment, has shown resilience in recent trading sessions amid cryptocurrency market dynamics. The stock has navigated volatility driven by Bitcoin's price fluctuations, reflecting broader sector sentiment.
In the ever-shifting healthcare sector, CVS Health (CVS) and UnitedHealth Group (UNH) represent two powerhouse approaches: CVS as a retail pharmacy giant with integrated insurance and services, and UNH as a leading health insurer with diversified operations.
In the competitive retail landscape, American Eagle Outfitters (NYSE: AEO) is showing signs of robust upward potential as it navigates a strong 2025 performance.
In the dynamic world of satellite communications and broadband services, EchoStar Corporation (NASDAQ: SATS) has captured investor attention with a notable technical breakthrough. On December 8, 2025, the stock's 10-day moving average crossed above its 50-day moving average, signaling the onset of a bullish upward trend.
In an era where global investors demand instant access to markets, major players in the financial world are racing to extend trading hours beyond the traditional 9:30 a.m. to 4 p.m. ET window. This push is driven by surging foreign holdings of U.S. equities, which hit $17 trillion last year, and the growing appetite for nonstop trading in a 24/7 digital economy.
In the resilient gold mining sector, IAMGOLD Corporation (NYSE: IAG) has demonstrated an extraordinary uptrend throughout 2025, capitalizing on rising gold prices and operational milestones.
Within the rapidly evolving automotive retail landscape, Carvana Co. (NYSE: CVNA) has emerged as one of 2025’s standout performers. Once viewed as a highly volatile name, the company has transformed into a market leader as demand for online vehicle purchasing accelerates
Microsoft (MSFT) emerges as the AI-favored stock in 2025, outperforming Apple (AAPL) with a 16% year-to-date gain, compared to Apple’s 10% rise. The advantage stems from Microsoft’s deeper enterprise AI integration, accelerating cloud growth, and scalable software ecosystem.
ExxonMobil (XOM) emerges as the AI-preferred energy stock in 2025, posting a 10% year-to-date gain compared with Chevron’s (CVX) 2% increase. Stronger upstream production, exposure to high-growth assets, and expanding low-carbon initiatives support XOM’s momentum. Tickeron’s AI models signal continued upside for XOM, while CVX shows signs of overbought conditions and elevated downside risk.
Tesla (TSLA) emerges as the AI-preferred EV stock in 2025, posting a 19% year-to-date gain, while BYD (BYDDY) has declined 82%, reflecting diverging momentum across the global EV market. Tickeron’s AI trading bots indicate strong bullish conditions for TSLA, supported by positive momentum signals, whereas BYDDY shows sustained bearish trends.
Broadcom (AVGO) emerges as the AI-preferred semiconductor stock in 2025, posting a 48% year-to-date gain, compared with 37% for NVIDIA (NVDA), supported by stronger diversification across networking, infrastructure, and custom AI chips.
- Bio-Techne carries a “Moderate Buy” consensus from 13 analysts, with an average price target of $70.58, implying about 15% upside. - Recent positive revisions include TD Cowen (Oct. 14, target raised from $65 to $70, Strong Buy), Evercore ISI (Oct. 7, $60 to $72, Buy), and RBC -
Skyworks Solutions (SWKS) has traded unevenly in recent weeks as investors digest shifting sector dynamics and company-specific guidance. The stock has moved into a consolidation phase following broader semiconductor rotations, with optimism in diversified end markets offset by ongoing pressure in mobile.
Seagate Technology (STX) has emerged as one of the standout performers of 2025, powered by explosive demand for data storage tied to artificial intelligence workloads. As hyperscalers expand cloud and AI infrastructure, Seagate’s high-capacity hard drives have become essential, pushing the stock sharply higher and keeping investor attention firmly locked on upcoming earnings.
Home Depot and Lowe’s are the two dominant players in the home improvement retail space, frequently compared due to their similar product offerings and overlapping customer bases of DIY homeowners and professional contractors. Their performance is closely watched as a barometer for consumer discretionary spending, housing market trends, and interest rate impacts.